Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism

Parkinsonism Relat Disord. 2008;14 Suppl 2(Suppl 2):S130-4. doi: 10.1016/j.parkreldis.2008.04.017. Epub 2008 Jun 27.

Abstract

Adenosine A(2A) antagonists can exert antiparkinsonian effects in animal models. Recent experiments studied the ability of MSX-3 (an adenosine A(2A) antagonist) to reverse the locomotor suppression and tremor produced by dopamine antagonists in rats. MSX-3 reversed haloperidol-induced suppression of locomotion, and reduced the tremulous jaw movements induced by haloperidol, pimozide, and reserpine. Infusions of MSX-3 into the nucleus accumbens core increased locomotion in haloperidol-treated rats, but there were no effects of infusions into the accumbens shell or ventrolateral neostriatum. In contrast, MSX-3 injected into the ventrolateral neostriatum reduced pimozide-induced tremulous jaw movements. Dopamine/adenosine interactions in different striatal subregions are involved in distinct aspects of motor function.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adenosine / metabolism*
  • Animals
  • Disease Models, Animal
  • Dopamine / metabolism*
  • Humans
  • Locomotion / physiology*
  • Parkinson Disease / etiology*
  • Tremor* / complications
  • Tremor* / metabolism
  • Tremor* / physiopathology

Substances

  • Adenosine
  • Dopamine